Incretin Based Therapies: Bone Protective Effects

Author(s): Marlene Chakhtoura, Sami T. Azar

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 13 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.

Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 24 February, 2014
Page: [289 - 294]
Pages: 6
DOI: 10.2174/18715303113136660046
Price: $65

Article Metrics

PDF: 49